Document Detail

A guide to the safety of CNS-active agents during breastfeeding.
MedLine Citation:
PMID:  9285203     Owner:  NLM     Status:  MEDLINE    
For most agents with CNS activity, there are limited data regarding their safety in breastfeeding. Any decision to institute treatment for a neurological or psychiatric disorder must weigh the benefits of maternal treatment against the potential harm to the breastfeeding mother of withholding medication which may improve her illness. For the neonate, one must balance the risk of medication exposure against the benefit of receiving breast milk. Most tricyclic antidepressants can be used in lactating women. Because of the limited data, selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors should only be used with due consideration of the potential adverse effects. Breastfeeding is best avoided by women who require lithium therapy, because of both the immature excretory systems in the infant and relatively high doses received by the infant. There is little information about the safety of antipsychotic medications in breastfeeding. Concerns include toxicity and abnormal neurological development in the infant. These agents may be used with caution. Most agents which cause depression of the CNS, including opiates and sedatives, can be used in small doses and for short courses in breastfeeding mothers. Most anticonvulsants can be used in lactating women. Reference texts and consultation with experts are useful adjuncts to discussion of the risks and benefits of therapy with the patient. The scope of this review is limited to drugs with therapeutic uses, thus drugs of abuse are not discussed, nor are caffeine and alcohol (ethanol).
C A Chisholm; J A Kuller
Related Documents :
16700683 - Motivational interviewing to promote sustained breastfeeding.
18336643 - Variation in breastfeeding behaviours, perceptions, and experiences by race/ethnicity a...
17538073 - Disparities in infant mortality: what's genetics got to do with it?
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drug safety     Volume:  17     ISSN:  0114-5916     ISO Abbreviation:  Drug Saf     Publication Date:  1997 Aug 
Date Detail:
Created Date:  1997-10-22     Completed Date:  1997-10-22     Revised Date:  2014-11-17    
Medline Journal Info:
Nlm Unique ID:  9002928     Medline TA:  Drug Saf     Country:  NEW ZEALAND    
Other Details:
Languages:  eng     Pagination:  127-42     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Breast Feeding*
Central Nervous System Agents / adverse effects*,  pharmacokinetics,  therapeutic use*
Reg. No./Substance:
0/Central Nervous System Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Role of desensitisation for drug hypersensitivity in patients with HIV infection.
Next Document:  Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes.